Merck & Co.’s Big Ambition To ‘Democratize’ PCSK9s

 
• By Jessica Merrill

Phase III studies testing the oral PCSK9 inhibitor MK-0616 for high cholesterol will begin in the second half of the year and include a broad program enrolling primary and secondary prevention patients.

go big
Merck & Co. is planning a big Phase III program for its oral PCSK9 inhibitor • Source: Shutterstock

More from Cardiovascular

More from Therapy Areas